L Durelli
Overview
Explore the profile of L Durelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
704
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghezzi A, Grimaldi L, Marrosu M, Pozzilli C, Comi G, Bertolotto A, et al.
Neurol Sci
. 2011 Jan;
32(2):351-8.
PMID: 21234775
Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own...
2.
Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, et al.
Expert Opin Biol Ther
. 2009 Mar;
9(4):387-97.
PMID: 19278300
Background: Neutralizing antibodies (NAbs) to IFN-beta may have a detrimental effect on treatment response, but increasing IFN-beta dose could reduce their occurrence. The OPTimization of Interferon for MS (OPTIMS) study...
3.
Clerico M, Faggiano F, Palace J, Rice G, Tintore M, Durelli L
Cochrane Database Syst Rev
. 2008 Apr;
(2):CD005278.
PMID: 18425915
Background: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if...
4.
Durelli L, Barbero P, Bergui M, Versino E, Bassano M, Verdun E, et al.
J Neurol Neurosurg Psychiatry
. 2007 Nov;
79(6):646-51.
PMID: 17986500
Objective: To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon beta treatment as response indicators in multiple sclerosis (MS). Methods: Patients with...
5.
Barbero P, Bergui M, Versino E, Ricci A, Zhong J, Ferrero B, et al.
Mult Scler
. 2006 Feb;
12(1):72-6.
PMID: 16459722
Background: In RRMS, clinical exacerbations are usually associated with different types of active lesions at MRI, including: hyperintense lesions on T1-weighted post-gadolinium sequences; new hyperintense lesions or enlarging old lesions...
6.
7.
Isoardo G, Bergui M, Durelli L, Barbero P, Boccadoro M, BERTOLA A, et al.
Acta Neurol Scand
. 2004 Feb;
109(3):188-93.
PMID: 14763956
Objective: Thalidomide is a promising therapy for multiple myeloma. Sensory neuropathy is a side effect of thalidomide and resulted to be partially reversible in 50% of cases, suggesting a sensory...
8.
Durelli L, Ricci A, Verdun E
Neurol Sci
. 2003 Nov;
24 Suppl 4:S234-8.
PMID: 14598050
In one of the most frequent MS demyelination patterns, IgG and complement are demonstrable on myelin surface. It is, probably, an antibody-mediated pattern of myelin damage, usually associated with acute...
9.
Cocito D, Durelli L, Isoardo G
Acta Neurol Scand
. 2003 Sep;
108(4):274-80.
PMID: 12956862
Chronic inflammatory demyelinating polyneuropathy (CIDP) is frequently associated with monoclonal gammopathies of undetermined significance (MGUS), Waldenström disease and osteosclerotic myeloma. There are still controversies about the role of these paraproteinaemias...
10.
Durelli L, Isoardo G
Neurol Sci
. 2002 May;
23 Suppl 1:S39-48.
PMID: 12032586
A review of the pathological basis of multiple sclerosis is presented to see whether the many immunological effects if IVIg may exert some benefit and at what level. This is...